Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood-brain barrier

Cancer Treatment Reviews

Volumn 39, Issue 3, 2013, Pages 261-269

  Mehta, Ankit I ^a   Brufsky, Adam M ^b   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Blood brain barrier; Brain metastases; Central nervous system; HER2 positive; Metastatic breast cancer; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; MOLECULAR SIZE; OVERALL SURVIVAL; POST HOC ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; STEREOTACTIC RADIOSURGERY; WHOLE BRAIN RADIOTHERAPY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 84873986858     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.05.006     Document Type: Review

References (107)

1. Patel R.R., Mehta M.P. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 2007, 13:1675-1683.
2. Vogelbaum M.A., Suh J.H. Resectable brain metastases. J Clin Oncol 2006, 24:1289-1294.
3. Chang J.E., Robins H.I., Mehta M.P. Therapeutic advances in the treatment of brain metastases. Clin Adv Hematol Oncol 2007, 5:54-64.
4. Palmieri D., Chambers A.F., Felding-Habermann B., Huang S., Steeg P.S. The biology of metastasis to a sanctuary site. Clin Cancer Res 2007, 13:1656-1662.
5. Miller K.D., Weathers T., Haney L.G., et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003, 14:1072-1077.
6. Lin N.U., Bellon J.R., Winer E.P. CNS metastases in breast cancer. J Clin Oncol 2004, 22:3608-3617.
7. Tsukada Y., Fouad A., Pickren J.W., Lane W.W. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983, 52:2349-2354.
8. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009, 27:5278-5286.
9. DiStefano A., Yong Yap Y., Hortobagyi G.N., Blumenschein G.R. The natural history of breast cancer patients with brain metastases. Cancer 1979, 44:1913-1918.
10. Patanaphan V., Salazar O.M., Risco R. Breast cancer: metastatic pattern and their prognosis. South Med J 1988, 81:1109-1112.
11. Engel J., Eckel R., Aydemir U., et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 2003, 55:1186-1195.
12. Arslan C., Dizdar O., Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother 2010, 11:1089-1100.
13. Gabos Z., Sinha R., Hanson J., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006, 24:5658-5663.
14. Hicks D.G., Short S.M., Prescott N.L., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006, 30:1097-1104.
15. Steeg P.S., Camphausen K.A., Smith Q.R. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011, 11:352-363.
16. Black P.M., Johnson M.D. Surgical resection for patients with solid brain metastases: current status. J Neurooncol 2004, 69:119-124.
17. Melisko M.E., Glantz M., Rugo H.S. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol 2009, 6:25-33.
18. Mahmoud-Ahmed A.S., Suh J.H., Lee S.Y., Crownover R.L., Barnett G.H. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 2002, 54:810-817.
19. Chang E.L., Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003, 8:398-410.
20. Noordijk E.M., Vecht C.J., Haaxma-Reiche H., et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994, 29:711-717.
21. Patchell R.A., Tibbs P.A., Walsh J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
22. Lee S.S., Ahn J.H., Kim M.K., et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 2008, 111:523-530.
23. Chang E.L., Wefel J.S., Hess K.R., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044.
24. Aoyama H., Shirato H., Tago M., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295:2483-2491.
25. Slotman B.J., Senan S. Radiotherapy in small-cell lung cancer: lessons learned and future directions. Int J Radiat Oncol Biol Phys 2011, 79:998-1003.
26. Paumier A., Cuenca X., Le Péchoux C. Prophylactic cranial irradiation in lung cancer. Cancer Treat Rev 2011, 37:261-265.
27. Huang F., Alrefae M., Langleben A., Roberge D. Prophylactic cranial irradiation in advanced breast cancer: a case for caution. Int J Radiat Oncol Biol Phys 2009, 73:752-758.
28. Lai R., Dang C.T., Malkin M.G., Abrey L.E. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004, 101:810-816.
29. Niwińska A., Tacikowska M., Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys 2010, 77:1134-1139.
30. Kaal E.C., Vecht C.J. CNS complications of breast cancer: current and emerging treatment options. CNS Drugs 2007, 21:559-579.
31. Sanna G., Franceschelli L., Rotmensz N., et al. Brain metastases in patients with advanced breast cancer. Anticancer Res 2007, 27:2865-2869.
32. Musolino A., Ciccolallo L., Panebianco M., et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 2011, 117:1837-1846.
33. Pestalozzi B.C., Zahrieh D., Price K.N., et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006, 17:935-944.
34. Kallioniemi O.P., Holli K., Visakorpi T., Koivula T., Helin H.H., Isola J.J. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991, 49:650-655.
35. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
36. Zhang L., Sullivan P.S., Goodman J.C., Gunaratne P.H., Marchetti D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res 2011, 71:645-654.
37. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
38. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
39. Altaha R., Crowell E., Hobbs G., Higa G., Abraham J. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma. Cancer 2005, 103:442-443.
40. Stemmler H.J., Kahlert S., Siekiera W., Untch M., Heinrich B., Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006, 15:219-225.
41. Yau T., Swanton C., Chua S., et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006, 45:196-201.
42. Dawood S., Broglio K., Esteva F.J., et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008, 19:1242-1248.
43. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57:173-185.
44. Régina A., Demeule M., Laplante A., et al. Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer Metastasis Rev 2001, 20:13-25.
45. Eichler A.F., Chung E., Kodack D.P., Loeffler J.S., Fukumura D., Jain R.K. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 2011, 8:344-356.
46. Zhang R.D., Price J.E., Fujimaki T., Bucana C.D., Fidler I.J. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 1992, 141:1115-1124.
47. Yonemori K., Tsuta K., Ono M., et al. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010, 116:302-308.
48. Eichler A.F., Loeffler J.S. Multidisciplinary management of brain metastases. Oncologist 2007, 12:884-898.
49. Stemmler H.J., Schmitt M., Willems A., Bernhard H., Harbeck N., Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007, 18:23-28.
50. Dijkers E.C., Kosterink J.G., Rademaker A.P., et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009, 50:974-981.
51. Jain R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990, 50(Suppl. 3):814s-819s.
52. Weinstein J.N., Eger R.R., Covell D.G., et al. The pharmacology of monoclonal antibodies. Ann NY Acad Sci 1987, 507:199-210.
53. Fujimori K., Covell D.G., Fletcher J.E., Weinstein J.N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990, 31:1191-1198.
54. Dijkers E.C., Oude Munnink T.H., Kosterink J.G., et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010, 87:586-592.
55. Grossi P.M., Ochiai H., Archer G.E., et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 2003, 9:5514-5520.
56. Lampson L.A. Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. MAbs 2011, 3:153-160.
57. van Vulpen M., Kal H.B., Taphoorn M.J., El-Sharouni S.Y. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy?. Oncol Rep 2002, 9:683-688.
58. Pestalozzi B.C., Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000, 18:2349-2351.
59. Sjögren S., Inganäs M., Lindgren A., Holmberg L., Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998, 16:462-469.
60. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
61. Owens M.A., Horten B.C., Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004, 5:63-69.
62. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847.
63. Yakes F.M., Chinratanalab W., Ritter C.A., King W., Seelig S., Arteaga C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62:4132-4141.
64. Le X.F., Pruefer F., Bast R.C. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 2005, 4:87-95.
65. Asanuma H., Torigoe T., Kamiguchi K., et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005, 65:11018-11025.
66. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61:4744-4749.
67. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
68. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416:279-280.
69. Niu G., Carter W.B. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res 2007, 67:1487-1493.
70. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
71. Perez E.A., Romond E.H., Suman V.J., et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007, 25(Suppl. 18S):6s. [Abstract 512].
72. Slamon D., Eiermann W., Robert N., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. Cancer Res 2009, 69(Suppl. 3):500s. [Abstract 62].
73. Bartsch R., Rottenfusser A., Wenzel C., et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007, 85:311-317.
74. Bartsch R., Berghoff A., Pluschnig U., et al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 2012, 106:25-31.
75. Brufsky A.M., Mayer M., Rugo H.S., et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011, 17:4834-4843.
76. Church D.N., Modgil R., Guglani S., et al. Extended survival in women with brain metastases from HER2-overexpressing breast cancer. Am J Clin Oncol 2008, 31:250-254.
77. Kirsch D.G., Ledezma C.J., Mathews C.S., et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005, 23:2114-2116.
78. Le Scodan R., Jouanneau L., Massard C., et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 2011, 11:395.
79. Nam B.H., Kim S.Y., Han H.S., et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008, 10:R20.
80. Park I.H., Ro J., Lee K.S., Nam B.H., Kwon Y., Shin K.H. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009, 20:56-62.
81. Park Y.H., Park M.J., Ji S.H., et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009, 100:894-900.
82. Witzel I., Kantelhardt E.J., Milde-Langosch K., et al. Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer. Onkologie 2011, 34:304-308.
83. Shigekawa T., Takeuchi H., Misumi M., et al. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast cancer 2009, 16:88-92.
84. Mir O., Ropert S., Alexandre J., Lemare F., Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 2008, 19:1978-1980.
85. Ferrario C., Davidson A., Bouganim N., Aloyz R., Panasci L.C. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 2009, 20:792-795.
86. Stemmler H.J., Mengele K., Schmitt M., et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 2008, 19:832-836.
87. Baculi R.H., Suki S., Nisbett J., Leeds N., Groves M. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol 2001, 19:3297-3298.
88. Church D.N., Bahl A., Jones A., Price C.G. HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab-a case report. J Neurooncol 2006, 79:289-292.
89. Smith QR, Rudraraju V, Taskar K, et al. Lapatinib distribution in brain metastases of breast cancer following oral dosing in mice. Presented at the Breast Cancer Symposium, Washington, DC, September 5-7, 2008. [Abstract 158].
90. Polli J.W., Humphreys J.E., Harmon K.A., et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008, 36:695-701.
91. Lin N.U., Carey L., Liu M.C., et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008, 26:1993-1999.
92. Lin N.U., Diéras V., Paul D., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15:1452-1459.
93. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:533-543.
94. Metro G., Foglietta L., Russillo M., et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011, 22:625-630.
95. Bachelot T.D., Romieu G., Campone M., et al. LANDSCAPE: an FNCLCC phase II study with lapatinib and capecitabine in patients with brain metastases from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). J Clin Oncol 2011, 29(Suppl.):47s. [Abstract 509].
96. Lin N.U., Eierman W., Greil R., et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011, 105:613-620.
97. De Azambuja E., Lemort M., Rossari J.R., et al. Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172). J Clin Oncol 2011, 29(Suppl.):62s. [Abstract 570].
98. Coombes R.C., Reise J.A., Lau M., et al. An open-label positron emission tomography (PET) study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing (HER2+) advanced or metastatic breast cancer (MBC). J Clin Oncol 2011, 29(Suppl.):8S. [Abstract TPS107].
99. Schulz H., Pels H., Schmidt-Wolf I., Zeelen U., Germing U., Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004, 89:753-754.
100. Rubenstein J.L., Fridlyand J., Abrey L., et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007, 25:1350-1356.
101. Ding D., Kanaly C.W., Bigner D.D., et al. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neurooncol 2010, 98:1-7.
102. Kunwar S., Chang S., Westphal M., et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 2010, 12:871-881.
103. Raghavan R., Brady M.L., Rodríguez-Ponce M.I., Hartlep A., Pedain C., Sampson J.H. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 2006, 20:E12.
104. Sampson J.H., Brady M., Raghavan R., et al. Co-localization of gadolinium-DTPA with high molecular weight molecules after intracerebral convection-enhanced delivery in man. Neurosurgery 2011, 69:668-676.
105. Vogelbaum M.A., Sampson J.H., Kunwar S., et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 2007, 61:1031-1037.
106. Hu J., Ljubimova J.Y., Inoue S., et al. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One 2010, 5:e10108.
107. Kinoshita M., McDannold N., Jolesz F.A., Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A 2006, 103:11719-11723.